Industry Symposia

  • Neurim  Pharmaceuticals
    Neurim Pharmaceuticals Addressing the unmet needs of children with ASD suffering from sleep disorders
    Neurim Pharmaceuticals

    Addressing the unmet needs of children with ASD suffering from sleep disorders

    Date / Location: 10.07.2017 / 07:30-08:30 CiCG

    Language: English

    Speaker: Nava Zisapel

    Sleep problems, generally defined as difficulty initiating and/or maintaining sleep, are one of the most common comorbid conditions experienced by individuals with autism spectrum disorder (ASD). Disrupted sleep worsens child's social interaction, day to day life, academic achievement, and correlates with increased maternal distress and parental sleep disruption.

    Bedtime routines and sleep hygiene is the mainstay of sleep management. If that fails, it should be combined with pharmacologic intervention but little evidence-based data exist to support such approach. To date, there are no approved medications to treat insomnia in pediatric patients, including ASD. Sleep medications are prescribed off-label although none was proven effective and safe in this population, leaving many families desperate for a better solution.

    The normal sleep–wake cycle is governed by the circadian clock residing in the hypothalamus. The clock is tuned by light and by its downstream signal of darkness hormone- melatonin. Mutations in genes involved in clock and melatonin pathways and low melatonin levels have been found in individuals with ASD, which may explain problems with sleep initiation and maintenance and/or early waking.

    Whereas a placebo-controlled randomized clinical trial (RCT) indicated that normal-release melatonin improves only sleep latency in children with neurodevelopmental disorders including ASD, a recently completed long-term placebo-controlled RCT indicated that prolonged-release melatonin (PRM) minitablets effectively improved both sleep latency and total sleep time (TST) in children with ASD.

    Behavioral treatment strategies along with PRM pharmacotherapy can help improve the quality of life of ASD children and decrease the family and parental distress.

    Neurim Pharmaceuticals | 27 HaBarzel St. | 69710 Tal Aviv | Israel

  • MEDICE Arzneimittel Pütter GmbH & Co. KG
    MEDICE Arzneimittel Pütter GmbH & Co. KG Industry Lunch Symposium
    MEDICE Arzneimittel Pütter GmbH & Co. KG

    ADHD in Children with Comorbid Conditions

    Date / Location: 10.07.2017 / 12:30-13:30 CiCG

    Language: English

    MEDICE ranks number 3 among family-owned pharmaceutical companies in Germany with own manufacturing, development, logistics and marketing nationally and internationally in more than 50 countries, through own subsidiaries or long-term partnerships. Committed to the fundamental ethical values of medicine, with 3 physicians in general management, MEDICE has been demonstrating for 65 years that long-term orientation and risk diversification are our strong basis for innovation and sustainable growth.
    MEDICE today is much more than just a producer of pharmaceuticals. It is a reliable partner, a fair employer and a dynamic driving force for medical progress.

    1st Contribution :
    ADHD, ASD and schizophrenia - comorbidities among neurodevelopmental disorders

    Speaker :
    Professor Jan Buitelaar
    Radboud University Nijmegen Medical Centre
    Department of Cognitive Neuroscience
    Donders Institute for Brain, Cognition and Behaviour,
    Nijmegen, The Netherlands.

    2nd contribution :
    ADHD & pathological internet and media use

    Speaker :
    Dr. med. Oliver Bilke-Hentsch MBA
    Consultant Child and Adolescent psychiatrist,
    Vice Director Modellstation SOMOSA, Winterthur (CH)
    Zurich, Switzerland

    MEDICE Arzneimittel Pütter GmbH & Co. KG | Kuhloweg 37 | 58638 Iserlohn | Deutschland